Development of an anti-influenza drug screening assay targeting nucleoproteins with tryptophan fluorescence quenching.

Recent studies have shown that NP (nucleoprotein), which possesses multiple functions in the viral life cycle, is a new potential anti-influenza drug target. NP inhibitors reliably induce conformational changes in NPs, and these changes may confer inhibition of the influenza virus. The six conserved tryptophan residues in NP can be used as an intrinsic probe to monitor the change in fluorescence of the tryptophan residues in the protein upon binding to an NP inhibitor. In the present study, we found that the fluorescence of recombinant NP proteins was quenched following the binding of available NP inhibitors (such as nucleozin) in a concentration- and time-dependent manner, which suggests that the inhibitor induced conformational changes in the NPs. The minimal fluorescence-quenching effect and weak binding constant of nucleozin to the swine-origin influenza virus H1N1pdm09 (SOIV) NP revealed that the SOIV is resistant to nucleozin. We have used the fluorescence-quenching property of tryptophans in NPs that were bound to ligands in a 96-well-plate-based drug screen to assess the ability of promising small molecules to interact with NPs and have identified one new anti-influenza drug, CSV0C001018, with a high SI value. This convenient method for drug screening may facilitate the development of antiviral drugs that target viruses other than the influenza virus, such as HIV and HBV.

[1]  Patricia Resa-Infante,et al.  The influenza virus RNA synthesis machine , 2011, RNA biology.

[2]  Daniel S. Chertow,et al.  Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. , 2011, The Journal of infectious diseases.

[3]  T. Noda,et al.  Structure of influenza virus ribonucleoprotein complexes and their packaging into virions , 2010, Reviews in medical virology.

[4]  S. Pal,et al.  Toward an alternative intrinsic probe for spectroscopic characterization of a protein. , 2010, The journal of physical chemistry. B.

[5]  Ying-Ta Wu,et al.  High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity , 2010, Proceedings of the National Academy of Sciences.

[6]  R. Webster,et al.  Drugs in Development for Influenza , 2010, Drugs.

[7]  Yi Guan,et al.  Identification of influenza A nucleoprotein as an antiviral target , 2010, Nature Biotechnology.

[8]  P. Mitrasinovic,et al.  Advances in the structure-based design of the influenza A neuraminidase inhibitors. , 2010, Current drug targets.

[9]  J. Gong,et al.  Potential targets and their relevant inhibitors in anti-influenza fields. , 2009, Current medicinal chemistry.

[10]  S. Kashiwagi,et al.  Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. , 2009, The Journal of infection.

[11]  S. Mossad,et al.  The First Pandemic of the 21st Century: Review of the 2009 Pandemic Variant Influenza A (H1N1) Virus , 2009, Postgraduate medicine.

[12]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[13]  H. Hsieh,et al.  Aurintricarboxylic acid inhibits influenza virus neuraminidase , 2008, Antiviral Research.

[14]  Pang-Chui Shaw,et al.  Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors , 2007, Nature Reviews Drug Discovery.

[16]  H. Hsieh,et al.  Strategies of development of antiviral agents directed against influenza virus replication. , 2007, Current pharmaceutical design.

[17]  C. Basler.  Influenza viruses: basic biology and potential drug targets. , 2007, Infectious disorders drug targets.

[18]  S. Boulo,et al.  Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. , 2007, Virus research.

[19]  R. Krug,et al.  The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA , 2006, Nature.

[20]  K. Meidtner,et al.  Determining the binding affinities of phenolic compounds to proteins by quenching of the intrinsic tryptophan fluorescence. , 2006, Molecular nutrition & food research.

[21]  R. Eccles,et al.  Understanding the symptoms of the common cold and influenza , 2005, The Lancet Infectious Diseases.

[22]  S. Stahl,et al.  Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters. , 2005, Journal of medicinal chemistry.

[23]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[24]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[25]  M. von Itzstein,et al.  Recent strategies in the search for new anti-influenza therapies. , 2003, Current drug targets.

[26]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[27]  J. Oxford,et al.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. , 2002, Antiviral research.

[28]  P. Digard,et al.  The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. , 2002, The Journal of general virology.

[29]  S. Moncheva,et al.  Intrinsic Tryptophan Fluorescence of Human Serum Proteins and Related Conformational Changes , 2000, Journal of protein chemistry.

[30]  A. Nafziger,et al.  Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. , 2000, Archives of internal medicine.

[31]  M. Ramanathan,et al.  A Rapid Spectrofluorimetric Technique for Determining Drug-Serum Protein Binding Suitable for High-Throughput Screening , 2000, Pharmaceutical Research.

[32]  P. Tappenden,et al.  Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. , 2011, The Journal of infection.

[33]  K. Mcintosh,et al.  The first influenza pandemic of the 21st century , 2010, Annals of Saudi medicine.

[34]  U. Dietrich,et al.  Targeting the viral nucleocapsid protein in anti-HIV-1 therapy. , 2008, Mini reviews in medicinal chemistry.

[35]  Ramkumar Hariharan,et al.  Detailed Comparison of the Protein-Ligand Docking Efficiencies of GOLD, a Commercial Package and ArgusLab, a Licensable Freeware , 2006, Silico Biol..